Abstract:( ) drug exporters contribute an efficient mechanism for drug resistance. Therefore, understanding the structure–function relationship in these proteins is important. We focused on the EfpA efflux pump, which belongs to the major facilitator superfamily (MSF) and transports anti-tuberculosis drugs outside the bacterial cell. Here, we report on our advancements in producing and characterization of this protein. We engineered a construct of apolipoprotein A-I (apoAI) fused to the N-terminus of EfpA (apoAI-EfpA) and cloned it in an expression vector. This fusion construct was found in a membrane-bound form, unlike the deposited in inclusion bodies EfpA without apoAI. We purified the apoAI-EfpA in detergent to a sufficient degree and reconstituted it in DOPC/DOPS lipids. We found that upon reconstitution in lipid, the apoAI-EfpA forms discoidal protein-lipid nanostructures with a diameter of about 20 nm, resembling nanodiscs. We further detected apoAI-EfpA oligomers in β-DDM and lipid. To the best of our knowledge, this is the first complete protocol on the expression, purification, and lipid reconstitution of the EfpA transported. AlphaFold2 also predicted EfpA oligomers and further bioinformatic analysis confirmed the earlier proposed 14-transmembrane helices of the EfpA. We also found very high identity, >80%, among the EfpA-s of diverse species. Outside of , EfpA has no close homologues with only low identity with the QacA family of transporters. These findings possibly indicate high specificity of EfpA mechanisms. Our developments provide a foundation for more comprehensive in vitro studies on the EfpA exporter.

What problem does this paper attempt to address?

The paper focuses on the study of the EfpA drug efflux pump in Mycobacterium tuberculosis. EfpA belongs to the major facilitator superfamily (MSF) and is involved in the efflux of anti-tuberculosis drugs from bacterial cells, leading to drug resistance. The research team constructed a fusion protein of Apolipoprotein A-I (apoAI) and the N-terminal of EfpA through protein engineering, successfully expressed and purified this fusion protein in Escherichia coli, and reconstituted it in lipid nanoparticles. The researchers found that apoAI-EfpA formed a disc-shaped protein-lipid nanostructure with a diameter of about 20nm in lipids, similar to a nanodisc. In addition, they observed the oligomerization of apoAI-EfpA in β-DDM and lipids. AlphaFold2 prediction suggested that EfpA may exist as an oligomer and confirmed the presence of 14 transmembrane α-helices in its membrane protein structure. EfpA showed high homology among different strains of Mycobacterium tuberculosis, but there was no close homolog in non-tuberculosis mycobacteria, indicating the specificity of EfpA mechanism. The results of the paper provide a foundation for a more comprehensive study of the EfpA efflux pump, aiding in understanding its interaction and transport mechanism with anti-tuberculosis drugs. This may potentially drive the development of strategies to inhibit EfpA and combat drug-resistant tuberculosis.

Protein engineering, production, reconstitution in lipid nanoparticles, and initial characterization of the EfpA drug exporter